Pharmacology and Toxicology
Showing page 14 of 22 pages of list content
-
An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity
This article's authors -
Genetic determinants of COVID-19 drug efficacy revealed by genome-wide CRISPR screens
This article's authors -
SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray
This article's authors -
Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation
This article's authors -
Nucleotide Analogues as Inhibitors of Viral Polymerases
This article's authors -
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms
This article's authors -
Discovery of rhodomyrtone as a broad-spectrum antiviral inhibitor with anti-SARS-CoV-2 activity
This article's authors -
In Vitro Efficacy of “Essential Iodine Drops” Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)
This article's authors -
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
This article's authors -
Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening
This article's authors